Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway

Curr Drug Discov Technol. 2011 Jun;8(2):119-25. doi: 10.2174/157016311795563820.

Abstract

Obesity has been associated with both the carcinogenesis and poor prognosis of colon cancer, one of the leading causes of cancer-related death. Increased blood levels of insulin in obese subjects have been demonstrated to play a key role in carcinogenesis. It is also possible that insulin affects treatment efficacy, leading to poor prognosis. In this study, we demonstrated that insulin can increase HT29 colon cancer cell line resistance to cycloheximide and 5-fluorouracil induced cytotoxicity. This effect can be inhibited by the PI3K/Akt inhibitor Ly294002, indicating the important role of this pathway in the insulin-induced inefficacy of chemotherapy. The insulin-induced resistance to cycloheximide and 5-fluorouracil can be used in drug screening to overcome the inefficacy of chemotherapy in obesity-associated colon cancer.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Survival / drug effects
  • Chromones / pharmacology
  • Colonic Neoplasms / enzymology*
  • Colonic Neoplasms / etiology
  • Colonic Neoplasms / pathology
  • Cycloheximide / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Enzyme Activation
  • Fluorouracil / pharmacology*
  • HT29 Cells
  • Humans
  • Insulin / metabolism*
  • Morpholines / pharmacology
  • Obesity / complications
  • Obesity / enzymology
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Oncogene Protein v-akt / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction / drug effects*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Chromones
  • Insulin
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Cycloheximide
  • Oncogene Protein v-akt
  • Fluorouracil